Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant

被引：38

作者：

Blot, N

Schneider, P

Young, P

Janvresse, C

Dehesdin, D

Tron, P

Vannier, JP

机构：

[1] Charles Nicolle Hosp, F-76000 Rouen, France

[2] Gen Hosp, Sallanches, France

来源：

BONE MARROW TRANSPLANTATION | 2000年 / 26卷 / 08期

关键词：

AML; bone marrow transplantation; herpes simplex virus infection; cidofovir;

D O I：

10.1038/sj.bmt.1702591

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

Herpes simplex virus (HSV) causes serious problems in immune-compromised patients such as those receiving a bone marrow transplant (BMT) for a hematological malignancy. Resistance to acyclovir (ACV) is a growing major concern. Foscarnet is a non-thymidine kinase-dependent agent, but the emergence of ACV and foscarnet-resistant HSV requires a new therapeutic approach. We describe a girl treated with cidofovir for a life-threatening ACV-resistant HSV infection after an unrelated BMT for a relapse of an acute myeloblastic leukemia (AML).

引用

收藏

页码：903 / 905

页数：3

相关论文

共 15 条

[1] New antiherpesvirus agents - Their targets and therapeutic potential [J].

Alrabiah, FA ;

Sacks, SL .

DRUGS, 1996, 52 (01) :17-32

[2] ACYCLOVIR GIVEN AS PROPHYLAXIS AGAINST ORAL ULCERS IN ACUTE MYELOID-LEUKEMIA - RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

BERGMANN, OJ ;

ELLERMANNERIKSEN, S ;

MOGENSEN, SC ;

ELLEGAARD, J .

BMJ-BRITISH MEDICAL JOURNAL, 1995, 310 (6988) :1169-1172

[3] Acyclovir-resistant herpes simplex virus infections in a bone marrow transplant population [J].

Darville, JM ;

Ley, BE ;

Roome, APCH ;

Foot, ABM .

BONE MARROW TRANSPLANTATION, 1998, 22 (06) :587-589

[4] FLUDARABINE AND ARABINOSYLCYTOSINE THERAPY OF REFRACTORY AND RELAPSED ACUTE MYELOGENOUS LEUKEMIA [J].

ESTEY, E ;

PLUNKETT, W ;

GANDHI, V ;

RIOS, MB ;

KANTARJIAN, H ;

KEATING, MJ .

LEUKEMIA & LYMPHOMA, 1993, 9 (4-5) :343-350

[5] Recurrent acyclovir-resistant herpes simplex in an immunocompromised patient: Can strain differences compensate for loss of thymidine kinase in pathogenesis? [J].

Horsburgh, BC ;

Chen, SH ;

Hu, A ;

Mulamba, GB ;

Burns, WH ;

Coen, DM .

JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (03) :618-625

[6]

LAM MT, 1981, CANCER, V48, P2168, DOI 10.1002/1097-0142(19811115)48:10<2168::AID-CNCR2820481009>3.0.CO

[7]

2-B

[8] Cidofovir [J].

Lea, AP ;

Bryson, HM .

DRUGS, 1996, 52 (02) :225-230

[9] Successful treatment of an acyclovir- and foscarnet-resistant herpes simplex virus type 1 lesion with intravenous cidofovir [J].

LoPresti, AE ;

Levine, JF ;

Munk, GB ;

Tai, CY ;

Mendel, DB .

CLINICAL INFECTIOUS DISEASES, 1998, 26 (02) :512-513

[10]

McCarthy AJ, 1999, MED PEDIATR ONCOL, V32, P411, DOI 10.1002/(SICI)1096-911X(199906)32:6<411::AID-MPO3>3.0.CO